This study is designed for adults who receive a kidney transplant. It will compare a standard anti-rejection therapy to an experimental anti-rejection therapy. The study will look carefully at how well the experimental anti-rejection therapy works and how it may be potentially less harmful to the transplanted kidney. Participants will be randomly assigned to receive either the standard therapy (CellCept & standard dose tacrolimus) or the experimental therapy combination(Zortress (everolimus) plus lower dose tacrolimus).
 
 

Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Imunosuppression Trial (BENEFIT)

This study is designed for adults who receive a kidney transplant. It is designed to compare standard anti-rejection medicine to an experimental anti-rejection medicine, Belatacept. It will look carefully at how well the anti-rejection medicine works and if it may be potentially less harmful to the transplanted kidney. Participants will be randomly assigned to receive standard medicine (cyclosporine) or the experimental medicine (Belatacept).